Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04700488

Magnetic Resonance Imaging (MRI) to Predict Outcomes of Pancreatic Ductal Adenocarcinoma (PDAC)

PDAC - Pancreatic Ductal Adenocarcinoma Clinical Trial

Official title:
MRI Imaging to Predict Outcomes of Treatment in PDAC Patients

Clinical Trial Summary

The purpose of this study is to assess if Six-Dimensional Magnetic Resonance Imaging (6D-MRI) is effective in predicting outcomes in patients with pancreatic ductal adenocarcinoma (PDAC).

Clinical Trial Description

The overarching goal of this pilot study is to evaluate the usefulness of a novel Magnetic Resonance Imaging (MRI) approach, which measure properties of tumor microenvironment (i.e. vascularity, fibrosis), to predict PDAC response to neoadjuvant therapy (NAT). ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04700488
Study type Interventional
Source Cedars-Sinai Medical Center
Contact Liliana Bancila
Phone 310-423-3872
Email Liliana.Bancila@cshs.org
Status Recruiting
Phase N/A
Start date May 19, 2022
Completion date January 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05642962 - Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC) Phase 1/Phase 2
Recruiting NCT06122896 - Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals Early Phase 1
Recruiting NCT05262855 - Study of [68Ga]FAPI-46 PET in Patients With Pancreatic Ductal Carcinoma Phase 2
Not yet recruiting NCT05947825 - Sitagliptin Combined With Gemcitabine and Albumin-bound Paclitaxel in PDAC Patients Phase 2
Recruiting NCT06151223 - A Prospective Registry for Patients at High-Risk for Pancreatic Cancer
Recruiting NCT05845801 - Prospective Registry of Young-Adult Patients Diagnosed With Pancreatic Cancer
Recruiting NCT05853198 - Circulating Tumor DNA as Surgical Biomarker in Patients With PancrEatic Adenocarcinoma for Statement of Resectability N/A
Recruiting NCT05669287 - Defining a Vascular Phenotype of Pancreatic Ductal Adenocarcinoma With CT Perfusion Using Quantitative Radiomics N/A
Recruiting NCT05727020 - Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
Recruiting NCT05218889 - Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer Phase 1/Phase 2
Recruiting NCT05132244 - Monitoring and Managing Glucose Levels in People With Pancreatic Cancer N/A
Recruiting NCT04365049 - Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma